Numerous efforts have been made to develop small molecule inhibitors to modulate reversible monoubiquitination of FANCD2 and inhibit the FA pathway, thereby augmenting the sensitivity of cancer cells to cytotoxic chemotherapy regimens, including platinum [12,50,51]. This evidence concerns the gene FANCA and cancer.